NSE: DIVISLAB · 7 October 2026
- Divi's Laboratories Ltd (DIVISLAB) shares edged higher by 0.40% on Tuesday, trading within a day's range of ₹9,495.50 to ₹9,659.00 against an opening price of ₹9,530.00.
- Divi's Laboratories Limited held its 36th Annual General Meeting via video conferencing, where shareholders approved all resolutions with the requisite majority. The meeting covered the adoption of standalone and consolidated financial statements for the financial year ended March 31, 2026, and the declaration of a dividend of ₹30 per equity share. Additionally, Mr. N.V. Ramana and Dr. Kiran S. Divi were re-appointed as directors after retiring by rotation.
- Trading volume was 0.93 times the 20-day average daily volume.
Why is Divi S Laboratories share price rising on 7 October 2026?
Divi's Laboratories Ltd (DIVISLAB) shares edged higher by 0.40% on Tuesday, trading within a day's range of ₹9,495.50 to ₹9,659.00 against an opening price of ₹9,530.00.
The broader market experienced downward pressure, with the Nifty benchmark declining 0.76% and the Nifty Pharma sector index slipping 0.43%. While the sector and broader indices closed in negative territory, Divi's Laboratories managed to post a modest gain, outperforming its immediate sectoral peers. This relative resilience follows a steady multi-day performance, including a 3.19% return over the preceding 5 trading days and a 1.05% return over the last 20 trading days.
The stock's movement reflects ongoing market sentiment following recent operational updates and corporate developments, including the company's annual general meeting held on August 10, 2026, where shareholders approved a final dividend of ₹30 per equity share for the financial year ended March 31, 2026. Management has continued to emphasize capacity ramp-ups at its Unit 3 facility near Kakinada and ongoing backward integration to strengthen supply reliability.
4.18 lakh shares traded by 7 October 2026 · 03:15 PM IST. This compares with a 20-day average daily volume of 4.50 lakh shares (0.93 times). The five-day average daily volume was 4.11 lakh shares. Separately, the NSE report for 6 October 2026 showed 2.95 lakh shares delivered, representing 63.42% of that day’s traded volume. The same report recorded 36,790 trades.
Divi's Laboratories gained 0.40% while outperforming a declining broader market and pharma sector index. Supported by a healthy delivery percentage of 63.42% and consistent multi-day returns, the price action reflects stable institutional and retail interest rather than a single confirmed intraday catalyst.
Latest Company Developments
Divi's Laboratories Limited held its 36th Annual General Meeting via video conferencing, where shareholders approved all resolutions with the requisite majority. The meeting covered the adoption of standalone and consolidated financial statements for the financial year ended March 31, 2026, and the declaration of a dividend of ₹30 per equity share. Additionally, Mr. N.V. Ramana and Dr. Kiran S. Divi were re-appointed as directors after retiring by rotation.
Confirms formal shareholder approval for the final dividend payout and leadership continuity as the company scales its manufacturing operations.
The company announced the cessation of senior management personnel Mr. L. Ramesh Babu (Vice President – Procurement) and Mr. D. Madhu Babu (Vice President – Projects) due to their retirement effective from the close of business hours on July 31, 2026. The disclosures were submitted in compliance with Regulation 30 of SEBI Listing Regulations.
Highlights key leadership transitions in critical operational divisions including procurement and project execution.
Divi's Laboratories submitted its audited standalone and consolidated financial results for the period ended March 31, 2026, alongside the recommendation of a final dividend of ₹30 per equity share. The board reported annual consolidated revenues of ₹11,682 crores and net income of ₹2,568 crores for the financial year. The record date for the dividend was subsequently set for July 24, 2026.
Provides the baseline full-year financial performance figures that underpin the company's valuation and capital return policies.
Divi's Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Divi's Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 14.66% on 30 September 2026. This compares with 13.87% on 30 June 2026, a change of +0.79 percentage points.
The filing reported 49 MF/UTI holders.
What to Watch Next
- Progress and commercial ramp-up timelines at the Greenfield Unit 3 facility near Kakinada
- Upcoming financial results announcement for the quarter ending September 30, 2026
- Delivery volume trends relative to the 20-day average volume of approximately 449,000 shares
- Regulatory audit updates and US FDA compliance status across manufacturing units 1 and 2
Other Dated Coverage
- Why Divi's Laboratories Shares Are Rising 3.85% Today | 6 October 2026 — 6 October 2026
- Why Divi's Lab Shares Fell 3.27% Today: Market Context & Analysis | 1 October 2026 — 1 October 2026
- Why Divi's Lab Shares Fell 1.48% Today: Sector Weakness & Context | 30 September 2026 — 30 September 2026
More Divi S Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Divi S Laboratories company news?
Divi's Laboratories Limited held its 36th Annual General Meeting via video conferencing, where shareholders approved all resolutions with the requisite majority. The meeting covered the adoption of standalone and consolidated financial statements for the financial year ended March 31, 2026, and the declaration of a dividend of ₹30 per equity share. Additionally, Mr. N.V. Ramana and Dr. Kiran S. Divi were re-appointed as directors after retiring by rotation.
How strong was Divi S Laboratories’s trading volume?
4.18 lakh shares traded, 0.93 times the 20-day average daily volume. The price and volume data are dated 7 October 2026 · 03:15 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.